AbbVie price target lowered to $212 from $221 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
Optimistic Outlook on AbbVie’s Emraclidine Strategy: A High-Reward Investment Opportunity
Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...
AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains
Shares of AbbVie Inc. ABBV rallied 1.37% to $173.70 Thursday, on what proved to be an all-around rough trading session for ...
What's In Store For Merck Stock In 2025?
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.
Benefits Pro5h
Ozempic among 15 drugs selected for Medicare drug price talks, Round 2, with Big Pharma
Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...
Global Glaucoma Market Predicted to Reach $2.5 Billion by 2033, New Report Shows - Growth Driven by Aging Populations and Innovative Therapies
Seven-Market Drug Forecast Analysis - Update" report has been added to ResearchAndMarkets.com's offering. Market Growth Driven by Aging Populations and Innovative TherapiesThe global glaucoma market ...
MarketWatch17h
Galapagos N.V. ADR
Teva Pharmaceutical Industries Ltd. ADR-0.51% $24.5B ...